Comparative efficacy of terlipressin and norepinephrine for treatment of hepatorenal syndrome-acute kidney injury: A systematic review and meta-analysis.
The treatment of choice for hepatorenal syndrome-acute kidney injury (HRS-AKI) is vasoconstrictor therapy in combination with albumin, preferably norepinephrine or terlipressin as recommended by recent guidelines. In the absence of larger head-to-head trials comparing the efficacy of terlipressin an...
Main Authors: | Jody C Olson, Ram M Subramanian |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2024-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0296690 |
Similar Items
-
Role of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Admitted to the ICU: A Substudy of the CONFIRM Trial
by: Constantine J. Karvellas, MD, et al.
Published: (2023-04-01) -
Terlipressin and albumin for the hepatorenal syndrome.
by: Antoniades, C, et al.
Published: (2003) -
Role of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Admitted to the ICU: A Substudy of the CONFIRM Trial: Erratum
Published: (2024-04-01) -
Low doses of terlipressin and albumin in the type I hepatorenal syndrome
by: Davide Pulvirenti, et al.
Published: (2013-05-01) -
Terlipressin versus placebo or noradrenalin in the treatment of hepatorenal syndrome: a systematic review and meta-analysis
by: Yue-Meng Wan, et al.
Published: (2024-09-01)